• ACCEL Lite: AHA Late-Breaker ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomized, Placebo-Controlled Trial

  • Nov 30 2023
  • Length: 12 mins
  • Podcast

ACCEL Lite: AHA Late-Breaker ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomized, Placebo-Controlled Trial

Listen for free

View show details

  • Summary

  • ORBITA-2 was designed to test whether stents reduce angina more than a placebo procedure in patients with single or multivessel disease on little or no antianginal medication at 12 weeks of follow up.

    In this interview, Christopher Rajkumar, MD, Rasha Al-Lamee, MD, and William E. Boden MD, FACC, discuss AHA Late-Breaker: Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
    Show more Show less
activate_WEBCRO358_DT_T2
Physical Illness & Disease Hygiene & Healthy Living
Show more Show less

What listeners say about ACCEL Lite: AHA Late-Breaker ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomized, Placebo-Controlled Trial

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available